Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| LQDA | LIQUIDIA CORP | $5.49B | 88,928,099 | 49.64% | 50.36% | Net Selling | Net Selling | ||
| SLNO | SOLENO THERAPEUTICS INC | $2.76B | 52,120,147 | 34.75% | 65.25% | Net Selling | Net Selling | ||
| CORT | CORCEPT THERAPEUTICS INC | $6.34B | 107,351,594 | 28.92% | 71.08% | Net Buying | Net Buying | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $39.85B | 133,512,573 | 82.21% | 17.79% | Net Selling | Net Selling | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.18B | 118,613,000 | 77.55% | 22.45% | Net Selling | Net Selling | ||
| KRYS | KRYSTAL BIOTECH INC | $8.90B | 29,479,756 | 79.90% | 20.10% | Net Selling | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $1.98B | 231,772,715 | 79.04% | 20.96% | Net Selling | Net Selling | ||
| VCEL | VERICEL CORP | $1.81B | 51,068,228 | 91.38% | 8.62% | Net Selling | Net Selling | ||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $1.08B | 172,642,055 | 60.94% | 14.28% | Net Selling | Net Buying | ||
| RPRX | ROYALTY PHARMA PLC | $30.55B | 575,832,204 | 61.86% | 17.33% | Net Selling | Net Selling | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $9.70B | 193,284,438 | 94.97% | 1.78% | Net Selling | Net Selling | ||
| OMER | OMEROS CORP | $896.01M | 72,375,355 | 42.57% | 5.00% | Net Buying | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $605.34M | 59,115,084 | 69.88% | 21.79% | Net Selling | Net Buying | ||
| ASND | ASCENDIS PHARMA A | $14.99B | 62,111,595 | 88.09% | 0.82% | Net Selling | Net Selling | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.00B | 62,742,820 | 29.88% | 70.12% | Net Selling | Net Selling | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $4.18B | 76,938,016 | 59.03% | 9.27% | Net Selling | Net Selling | ||
| LGND | LIGAND PHARMACEUTICALS INC | $4.36B | 20,041,061 | 18.49% | 81.51% | Net Selling | Net Selling | ||
| SPRO | SPERO THERAPEUTICS INC | $152.28M | 57,901,493 | 36.38% | 62.38% | Net Selling | Net Selling | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.82B | 57,892,676 | 78.88% | 21.12% | Net Selling | Net Selling | ||
| TECH | BIO-TECHNE CORP | $7.31B | 156,568,751 | 97.83% | 2.17% | Net Selling | Net Selling | ||
| TGTX | TG THERAPEUTICS INC | $6.09B | 153,083,580 | 58.59% | 41.41% | Net Selling | |||
| EXEL | EXELIXIS INC | $12.54B | 251,355,083 | 94.82% | 5.18% | Net Selling | Net Selling | ||
| UTHR | UNITED THERAPEUTICS CORP | $23.94B | 42,446,733 | 86.74% | 13.26% | Net Selling | Net Selling | ||
| NAGE | NIAGEN BIOSCIENCE INC | $298.67M | 79,644,327 | 20.68% | 79.32% | Net Buying | Net Buying | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.82B | 122,380,992 | 84.15% | 15.85% | Net Selling | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $109.25B | 253,805,417 | 91.36% | 1.52% | Net Selling | Net Selling | ||
| VCYT | VERACYTE INC | $3.61B | 79,792,647 | 67.19% | 32.81% | Net Selling | Net Selling | ||
| MDXG | MIMEDX GROUP INC | $564.50M | 148,945,731 | 48.19% | 51.81% | Net Buying | Net Buying | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $161.95M | 80,571,642 | 10.86% | 89.14% | Net Buying | |||
| REGN | REGENERON PHARMACEUTICALS INC | $68.12B | 104,839,032 | 68.45% | 31.55% | Net Selling | Net Selling | ||
| INCY | INCYTE CORP | $19.39B | 199,782,155 | 77.94% | 22.06% | Net Selling | Net Buying | ||
| SRPT | SAREPTA THERAPEUTICS INC | $1.81B | 105,576,222 | 77.41% | 22.59% | Net Selling | Net Selling |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.